Pharmafile Logo

Dementia Consortium

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval

Leqembi was granted accelerated approval earlier this year for patients with early Alzheimer's disease

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

Eli Lilly to acquire Sigilon in deal worth over $300m

The companies have been working together since 2018 on cell therapies for type 1 diabetes

- PMLiVE

FDA grants fast track designation to AC Immune’s Alzheimer’s disease vaccine

The decision was supported by interim results from a low dose cohort of the phase 1b/2 ABATE trial

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

- PMLiVE

Alzheimer’s Research UK and Race Against Dementia announce £500k research pledge

The funding will allow researchers to investigate the link between air pollution and Alzheimer’s disease

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug backed by FDA advisory committee for traditional approval

Leqembi was granted accelerated approval by the FDA in January for patients with early AD

- PMLiVE

MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer

More than 9,700 people are diagnosed with womb cancer each year in the UK

- PMLiVE

Research finds a third with dementia concerns face long wait for medical help

It is estimated that by 2040 1.6m people will suffer from dementia in the UK

- PMLiVE

Eli Lilly’s Alzheimer’s drug shown to significantly slow disease progression in phase 3 trial

Donanemab slowed the progression of early Alzheimer’s disease by 35% compared to placebo

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links